Home
Scholarly Works
Treatment Response With VRDN-001, a Full...
Journal article

Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

Authors

Katz B; Turbin R; Cockerham K; Tang R; Nijhawan N; Ugradar S; O'Shaughnessy DJ; Summerfelt RM; She A; Douglas R

Journal

Endocrine Abstracts, , ,

Publisher

Bioscientifica

Publication Date

May 2, 2023

DOI

10.1530/endoabs.90.p750

ISSN

1470-3947
View published work (Non-McMaster Users)

Contact the Experts team